Pharmaceutical companies have been raising the price of prescription drugs at an alarming rate since 2010.
According to a new report from The Wall Street Journal, the 30 highest-selling drugs in the United States saw their prices increase roughly 76% from 2010 through 2014.
Pharmaceutical companies have been raising the price of prescription drugs at an alarming rate since 2010.
According to a new report from The Wall Street Journal, the 30 highest-selling drugs in the United States saw their prices increase roughly 76% from 2010 through 2014.
And as they've raised prices, their profits have soared...
Biotech stocks have gotten crushed in recent weeks, with the Nasdaq Biotechnology Index falling 15.5% in the last month and 25% from its July highs.
And while many investors are taking their money to the sideline, this is actually a great time to invest in biotech ETFs with 2016 in mind.
Here's the biotech ETF we're recommending now...
Start the conversation
Leave a Reply
Another possible deal between two of the world's top pharmaceutical companies was announced this week when Shire Plc. (Nasdaq: SHPG) made an unsolicited offer of $30.6 billion for Baxalta Inc. (NYSE: BXLT).
Money Morning Defense & Tech Specialist Michael A. Robinson has been following this trend since 2014. He knew the world's top pharmaceutical companies would continue their M&A binge, and he recommended an investment to play that wave.
Robinson's pick has already climbed 17.6% this year and still has plenty of room to run...
The world's top pharma companies bring in billions in revenue every year, sometimes from only a few products.
That's the case with each of these top pharma companies. This chart shows the most expensive prescription drugs in the world. The most expensive drug, Soliris, costs each patient $409,500 every year.
Here are the seven most expensive drugs in the world:
Start the conversation
Leave a Reply
Two top pharmaceutical companies announced a merger this morning, continuing 2015's massive run of M&A activity.
Botox maker Allergan Plc. (NYSE: AGN) announced today that it will purchase Kythera Biopharmaceuticals Inc. (Nasdaq: KYTH) for $2.1 billion. That values KYTH shares at $75 each - 24% higher than Tuesday's closing price.
Start the conversation
Leave a Reply
The pharmaceutical industry saw record-setting M&A activity in the first quarter of 2015.
According to PricewaterhouseCoopers, the "life sciences" field had 35 deals in Q1 2015. Those deals totaled $166.3 billion. That's more money than was spent during the entire year in 2014, when $150.1 billion was spent. In Q1 2014, just $46.5 billion was spent.
Money Morning's Defense and Tech Specialist Michael Robinson has been recommending a way to profit from the M&A boom throughout 2015.
Start the conversation
Leave a Reply
Two of the world's top pharmaceutical companies have announced a merger today (Thursday), and that's another major buy signal for one of our favorite profit opportunities.
AbbVie Inc. (NYSE: ABBV) officials announced they will purchase Pharmacyclics Inc. (Nasdaq: PCYC) for roughly $21 billion.
The deal gives Abbvie access to one of the world's top-selling cancer drugs, Imbruvica. Revenue from Imbruvica alone is expected to hit $1 billion in 2015 and $5.8 billion by 2020.
Start the conversation
Leave a Reply
Pharmaceutical stocks can plummet for myriad reasons: loss of funding, lawsuits, poor clinical trials.
It's a risky sector to get yourself involved in - one with big rewards. But, where there are big rewards, there are also big losses.
We took a look at five pharmaceutical stocks you should avoid...
Antibiotic-resistant microorganisms are turning into a national medical nightmare, and the need for new, more effective medications to treat them has reached critical mass.
In response, the U.S. government and the pharmaceutical industry are joining forces to handle the crisis - and extraordinary opportunities are beckoning the savvy investor.
The Centers for Disease Control and Prevention (CDC) estimates that in the U.S. alone, antibiotic-resistant bacteria make 2 million people sick and 23,000 die each year.
Estimates of the annual cost to the economy range up to $35 billion in excess medical expenses and another $35 billion in lost productivity.
It's a problem that isn't going away. In fact, it's getting worse...
Start the conversation
Leave a Reply
Pharmaceutical stocks soar when their companies receive FDA approval. The key to investing in the pharmaceutical sector is research: you've got to know when, how and if the company you like will profit.
That's why we've compiled a list of the leading pharmaceutical stocks around.
Have a look at these drug companies yielding impressive gains while they treat diseases...
Start the conversation
Leave a Reply
Last week's $45.2 billion Time Warner-Comcast deal pushed the global deal tally to $336 billion so far this year - the most since 2007 - and another blockbuster deal announced this week will push that figure even higher.
On Tuesday Irish drugmaker Actavis PLC (NYSE: ACT), producer of generic and specialty urology and women's health products, agreed to buy New York-based Forest Laboratories Inc. (NYSE: FRX) for $25 billion.
To continue reading, please click here...
Start the conversation
Leave a Reply
While gains were modest across the three major benchmarks today (Tuesday), there was nothing modest about these major gains for Furiex Pharmaceuticals (Nasdaq: FURX) stock.
Shares of Furiex more than doubled in value, surging some 150% intraday. The closed up 129.91% at $105.69. The reason: The company announced that its experimental drug eluxadoline significantly alleviated diarrhea and abdominal pain, which typically accompany irritable bowel syndrome (IBS), in two large late-stage trials.
To continue reading, please click here...
Start the conversation
Leave a Reply
They account for 264 million prescriptions annually in the U.S. alone, and $35 billion in annual global sales. Now doctors say these drugs could help treat an entirely different ailment, which affects hundreds of millions of people worldwide. That means sales are about to skyrocket.
And just two drug companies will reap the lion's share of the profits...
Start the conversation